Dr. Reddy's Laboratories' (Charlotte, NC) core mission is twofold: to provide patients access to high-quality generic medicines at affordable prices and develop new treatments to satisfy unmet medical needs and improve existing therapies.
Dr. Reddy's started its generic operations in 2001, marketing its products principally in the United States, Canada, and the European Union. In North America, the company currently markets 33 products in more than 147 presentations under its label.
The company has an aggressive generic pipeline and in the last year launched such prescription generic products as zolpidem, terbinafine, carvedilol, ramipril, and venlafaxine, as well as generic OTC products, such as ranitidine 150-mg tablets and cetirizine 10-mg tablets. It also is uniquely positioned to support Rx to OTC switches through its OTC group.
Dr. Reddy's product development capabilities, state-of-the-art manufacturing facilities, and access to its own active pharmaceutical ingredients offer significant supply chain efficiencies.
To further expand these capabilities, Dr. Reddy's recently announced the acquisition of the BASF pharmaceutical contract manufacturing business, including the relevant business, customer contracts, related Abbreviated New Drug Applications (ANDAs), and trademarks, as well as the BASF manufacturing facility and assets in Shreveport, Louisiana. The facility manufactures solid, semisolid, and liquid dosage forms and has a proven track record of achieving compliance with regulatory bodies, including the FDA.
|Recent New Products from Dr. Reddy's|
Ramipril is the AB-rated generic equivalent to Altace. It is available in 1.25-, 2.5-, 5-, and 10-mg capsules in bottles of 90 capsules each.
Carvedilol is the AB-rated generic equivalent to Coreg. It is available in 3.125-, 6.25-, 12.5-, and 25-mg tablets in bottles of 100 tablets each.
"We are excited about this acquisition, as this facility provides us with a profitable revenue base built on strong customer relationships with branded and generic companies," noted Mark Hartman, president of North America Generics at Dr. Reddy's. "It also provides us with an additional platform to further expand our prescription generic and OTC capabilities, and our general product portfolio, as well as the ability to supply generic products to US government agencies."
The future will see the company expand into additional dosage forms, including injectables, liquids, topicals, inhalers, and controlled substances. Dr. Reddy's goal by 2010 is to have more than 120 internally developed ANDA products marketed in the United States, with another 50+ products in-licensed from partners.
Through the coordinated efforts of teams throughout the world, Dr. Reddy's constantly seeks to expand its pipeline of generic products, making medicines more accessible and affordable to people all over the world.
For more information, visit www.drreddys.com.